Baccolini Valentina, da Silva Lígia Pereira, Teixeira Liliana, de Sousa Raquel Teixeira, Manarte-Monteiro Patrícia
FP-I3ID, Faculty of Health Sciences, University Fernando Pessoa, 4200-150 Porto, Portugal.
RISE-Health, University Fernando Pessoa, 4200-150 Porto, Portugal.
J Funct Biomater. 2025 Jul 25;16(8):272. doi: 10.3390/jfb16080272.
Amorphous calcium phosphate (ACP) is a well-established bioceramic material known to promote the remineralization of dental hard tissues. White spot lesions (WSLs) represent the initial stage of enamel demineralization and are frequently observed in patients with fixed orthodontic appliances or inadequate oral hygiene. Although recommendations for remineralizing agents include both the prevention of lesion progression and the stimulation of tissue remineralization, the clinical efficacy of ACP-based materials remains under debate. This systematic review, registered in the PROSPERO database (CRD42024540595), aims to evaluate the clinical efficacy of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)-based products in the remineralization of WSLs and to compare these outcomes with those achieved using non-bioceramic approaches. Inclusion criteria comprised randomized clinical trials, prospective cohort studies, and pilot studies conducted on human subjects with WSLs affecting permanent teeth. Studies involving artificial WSLs or non-cariogenic enamel lesions were excluded. The quality of the included studies was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Fourteen articles met the inclusion criteria and were analyzed. The main findings indicate that CPP-ACP is clinically effective in promoting the remineralization of WSLs, although the results were inconsistent across studies. Comparisons with placebo and resin infiltration treatments revealed greater efficacy for CPP-ACP. The combination of CPP-ACP with fluoride appeared to further enhance the remineralizing effect on WSLs. Additional standardized clinical studies with longer follow-up periods are warranted to confirm these outcomes.
无定形磷酸钙(ACP)是一种公认的生物陶瓷材料,已知可促进牙齿硬组织的再矿化。白斑病变(WSLs)代表牙釉质脱矿的初始阶段,在佩戴固定正畸矫治器或口腔卫生不良的患者中经常观察到。尽管对再矿化剂的建议包括预防病变进展和刺激组织再矿化,但基于ACP的材料的临床疗效仍存在争议。本系统评价已在PROSPERO数据库(CRD42024540595)中注册,旨在评估基于酪蛋白磷酸肽-无定形磷酸钙(CPP-ACP)的产品在WSLs再矿化中的临床疗效,并将这些结果与使用非生物陶瓷方法取得的结果进行比较。纳入标准包括对患有影响恒牙的WSLs的人类受试者进行的随机临床试验、前瞻性队列研究和试点研究。涉及人工WSLs或非致龋性牙釉质病变的研究被排除。使用Cochrane偏倚风险2(RoB 2)工具评估纳入研究的质量。14篇文章符合纳入标准并进行了分析。主要研究结果表明,CPP-ACP在促进WSLs再矿化方面具有临床效果,尽管各研究结果不一致。与安慰剂和树脂浸润治疗的比较显示CPP-ACP具有更高的疗效。CPP-ACP与氟化物的联合使用似乎进一步增强了对WSLs的再矿化作用。有必要进行更多随访期更长的标准化临床研究以证实这些结果。